Contrasting Moderna (MRNA) & Its Competitors

Moderna (NASDAQ:MRNA) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Moderna to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Earnings & Valuation

This table compares Moderna and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moderna	$1.94 billion	-$2.82 billion	-31.46
Moderna Competitors	$728.85 million	$11.28 million	-18.80

Moderna has higher revenue, but lower earnings than its competitors. Moderna is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Moderna has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Moderna’s competitors have a beta of -1.88, suggesting that their average share price is 288% less volatile than the S&P 500.

Profitability

This table compares Moderna and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-110.46%	-25.79%	-15.85%
Moderna Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a breakdown of recent recommendations for Moderna and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4	15	6	0	2.08
Moderna Competitors	9903	15310	45655	1602	2.54

Moderna presently has a consensus price target of $113.75, suggesting a potential downside of 49.08%. As a group, “Biotechnology” companies have a potential upside of 128.92%. Given Moderna’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Moderna has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

75.3% of Moderna shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Moderna competitors beat Moderna on 7 of the 13 factors compared.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.